New York Congressman Collins indicted for insider trading of biotech stocks

Amy Baxter | | Health Exec | Management
Stocks

Rep. Chris Collins, R-New York, has been indicted on charges of insider trading related to his holdings in biotechnology stocks.

Collins, who served on the board of directors of Australian company Innate Immunotherapeutics, possessed nonpublic information and shared it with his son and others, including his son’s fiancée’s father, the U.S. Department of Justice alleges. Collins provided a tip about the results of an upcoming drug trial before it was public, saving the Congressman’s son, Cameron Collins, and the father of Cameron Collin’s fiancée, Stephen Zarsky, approximately $768,000.

Furthermore, the three allegedly made false statements to the FBI to cover up their participation in inside trading. All three are charged with conspiracy, securities fraud, wire fraud and making false statements to the FBI. All three have pleaded not guilty.

Collins was the first Republican in Congress to support President Donald Trump’s candidacy and is known for being loose-lipped with the media, Vox reported.

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.